HC Wainwright Analysts Raise Earnings Estimates for RenovoRx

RenovoRx, Inc. (NASDAQ:RNXT) – Investment analysts at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for shares of RenovoRx in a research note issued on Monday, August 18th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($0.31) per share for the year, up from their previous estimate of ($0.32). HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for RenovoRx’s current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for RenovoRx’s Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.30) EPS.

RenovoRx (NASDAQ:RNXT) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.08). The firm had revenue of $0.42 million for the quarter, compared to analyst estimates of $0.25 million.

A number of other research analysts have also recently issued reports on RNXT. Wall Street Zen cut RenovoRx from a “hold” rating to a “sell” rating in a research note on Saturday, August 2nd. Ascendiant Capital Markets lifted their price objective on RenovoRx from $11.00 to $11.50 and gave the company a “buy” rating in a report on Thursday, June 5th. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, RenovoRx currently has a consensus rating of “Buy” and a consensus target price of $7.25.

RenovoRx Stock Down 5.6%

Shares of RNXT stock opened at $0.87 on Wednesday. RenovoRx has a 12-month low of $0.75 and a 12-month high of $1.6899. The firm has a fifty day moving average of $1.26 and a 200-day moving average of $1.13. The firm has a market capitalization of $31.89 million, a price-to-earnings ratio of -2.29 and a beta of 1.26.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. bought a new stake in RenovoRx in the 2nd quarter valued at $98,000. Geode Capital Management LLC increased its holdings in shares of RenovoRx by 9.9% in the second quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock valued at $467,000 after purchasing an additional 31,730 shares during the last quarter. AWM Investment Company Inc. bought a new position in shares of RenovoRx in the first quarter valued at about $2,262,000. Alyeska Investment Group L.P. acquired a new stake in shares of RenovoRx during the 1st quarter worth about $682,000. Finally, ADAR1 Capital Management LLC lifted its stake in shares of RenovoRx by 143.3% during the 1st quarter. ADAR1 Capital Management LLC now owns 479,883 shares of the company’s stock worth $475,000 after buying an additional 282,633 shares during the last quarter. 3.10% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other RenovoRx news, insider Ramtin Agah purchased 21,000 shares of the stock in a transaction on Thursday, June 5th. The shares were purchased at an average price of $1.40 per share, with a total value of $29,400.00. Following the completion of the transaction, the insider directly owned 734,460 shares in the company, valued at $1,028,244. This represents a 2.94% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 9.13% of the company’s stock.

About RenovoRx

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.